Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 474121 in Ketamine-Induced Cognitive Deficits
NCT05451095Phase 1Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of BI 474121 in schizophrenia and Alzheimer's disease (AD) (6 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Difference between the total number of errors adjusted for stages that subjects did not complete in the paired associate learning test (PALTEA28), post-ketamine minus the PALTEA28 pre-ketamine up to 22 days. Planned start Nov 2022; status: withdrawn.
02
Drugs
BI 474121
03
Conditions
schizophreniaAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05451095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05451095.